BioInsights - Major bioprocessing challenges & considerations with gene therapies and ex vivo gene-edited cell therapy
Raw Materials 2019

Major bioprocessing challenges & considerations with gene therapies and ex vivo gene-edited cell therapy

Cell & Gene Therapy Insights 2019; 5(10), 1225-1227.

10.18609/cgti.2019.128

Published: 1 November 2019
Interview
Andy Ramelmeier

Andy Ramelmeier

Andy Ramelmeier currently serves as Executive Vice President and Chief Manufacturing and Quality Officer and is responsible for Technical Operations at Sangamo, including manufacturing, quality supply chain, and process and analytical development. Dr Ramelmeier has 25 years of experience in the biopharmaceutical industry, developing and transferring biological processes, designing and building manufacturing facilities, and directing contract manufacturers as well as internal manufacturing operations. Prior to joining Sangamo in January 2018, he served as Senior Vice President, Technical Operations at Portola Pharmaceuticals, Inc., where he was responsible for tech transfer, bulk and drug product manufacturing, technical support and supply chain of Portola’s pipeline products. From 2006 to 2014, Dr Ramelmeier served as Vice President, Manufacturing, Process Sciences and Facilities at BioMarin, overseeing multiple commercial biologics products, clinical pipeline, and facilities in Novato, CA, and Shanbally, Ireland. Earlier in his career, he held roles of increasing responsibility at Johnson & Johnson and Merck. Prior to joining industry, Dr Ramelmeier conducted post-doctoral work in Germany. He received a BSc in Chemical Engineering from Johns Hopkins and his PhD in Chemical Engineering from the University of California, Berkeley.